Stock BMY BRISTOL-MYERS SQUIBB COMPANY
Add to a list
To use this feature you must be a member
Log inSign up

Bristol-Myers Squibb Company Stock

Equities

BMY

US1101221083

Pharmaceuticals

Market Closed - Nyse
Other stock markets
 04:00:02 2024-04-18 pm EDT 		5-day change 1st Jan Change
48.3 USD +0.96% Intraday chart for Bristol-Myers Squibb Company -1.67% -5.87%
Apr. 18 Wells Fargo Adjusts Bristol-Myers Squibb's Price Target to $52 From $51, Keeps Equalweight Rating MT
Apr. 17 TORL BioTherapeutics LLC announced that it has received $158.3 million in funding from a group of investors CI

Financials (USD)

Sales 2024 * 45.83B Sales 2025 * 46.36B Capitalization 97.89B
Net income 2024 * -3.95B Net income 2025 * 10.31B EV / Sales 2024 * 2.98 x
Net Debt 2024 * 38.57B Net Debt 2025 * 30.42B EV / Sales 2025 * 2.77 x
P/E ratio 2024 *
-33.2 x
P/E ratio 2025 *
8.78 x
Employees 34,100
Yield 2024 *
5.01%
Yield 2025 *
5.23%
Free-Float 69.13%
More Fundamentals * Assessed data

Chart Bristol-Myers Squibb Company

Dynamic Chart

Latest news about Bristol-Myers Squibb Company

Wells Fargo Adjusts Bristol-Myers Squibb's Price Target to $52 From $51, Keeps Equalweight Rating MT
TORL BioTherapeutics LLC announced that it has received $158.3 million in funding from a group of investors CI
Asher Biotherapeutics, Inc. announced that it has received $55 million in funding from a group of investors CI
Wolfe Research Adjusts Price Target on Bristol-Myers Squibb Company to $55 From $57, Outperform Rating Kept MT
Wolfe Research Adjusts Price Target on Bristol-Myers Squibb to $55 From $57, Maintains Outperform Rating MT
Jefferies Cuts Bristol-Myers Squibb's Price Target to $56 From $58 MT
TORL BioTherapeutics LLC announces tranche update CI
Bristol Myers: cancer treatment results CF
Morgan Stanley Trims Price Target on Bristol-Myers Squibb to $40 From $41, Keeps Underweight Rating MT
Bristol Myers Squibb Announces KRAZATI in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer CI
Global markets live: Boeing, Shell, AstraZeneca, Tesla, Meta... Our Logo
Bristol Myers: new data on schizophrenia CF
Bristol Myers' schizophrenia drug reduces symptoms without weight gain in late-stage studies RE
Bristol-Myers Squibb, 2seventy Bio Say FDA Approves Expansion of Myeloma Treatment's Indication MT
Bristol Myers, 2seventy Get FDA OK for Earlier Abecma Use in Multiple Myeloma DJ
More news

Latest transcript on Bristol-Myers Squibb Company

Logo Bristol-Myers Squibb Company
Bristol-Myers Squibb Company Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-14-2024 08:30 AM
More transcripts

Analyst Recommendations on Bristol-Myers Squibb Company

Wells Fargo Adjusts Bristol-Myers Squibb's Price Target to $52 From $51, Keeps Equalweight Rating MT
Wolfe Research Adjusts Price Target on Bristol-Myers Squibb Company to $55 From $57, Outperform Rating Kept MT
Wolfe Research Adjusts Price Target on Bristol-Myers Squibb to $55 From $57, Maintains Outperform Rating MT
Jefferies Cuts Bristol-Myers Squibb's Price Target to $56 From $58 MT
Morgan Stanley Trims Price Target on Bristol-Myers Squibb to $40 From $41, Keeps Underweight Rating MT
More recommendations

Press releases Bristol-Myers Squibb Company

Actinium Pharmaceuticals (ATNM) Garners Attention with Clinical Successes and Strategic Market Moves Amid Growing Radiopharma Interest AQ
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Squibb Company - BMY PR
KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC) BU
U.S. FDA Approves Bristol Myers Squibb and 2seventy bio's Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma after Two Prior Lines of Therapy AQ
 Bristol Myers Squibb Presents New Pooled Interim Long-Term Safety and Metabolic Outcomes Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society BU
More press releases

News in other languages on Bristol-Myers Squibb Company

Bristol Myers : résultats d'un traitement pour le cancer
EE.UU. - Valores a seguir en Wall Street (actualizado)
Bristol Myers : de nouvelles données sur la schizophrénie
Bristol Myers : la FDA valide Abecma dans le myélome multiple
Bristol Myers : approbation élargie pour Reblozyl dans l'UE
More news

Quotes and Performance

1 day+0.96%
1 week-1.67%
Current month-10.93%
1 month-6.38%
3 months-3.57%
6 months-15.04%
Current year-5.87%
More quotes

Highs and lows

1 week
47.62
Extreme 47.615
49.10
1 month
47.62
Extreme 47.615
54.48
Current year
47.58
Extreme 47.58
55.04
1 year
47.58
Extreme 47.58
70.94
3 years
47.58
Extreme 47.58
81.44
5 years
42.48
Extreme 42.48
81.44
10 years
42.48
Extreme 42.48
81.44
More quotes

Managers and Directors - Bristol-Myers Squibb Company

Managers TitleAgeSince
Christopher Boerner CEO
 Chief Executive Officer 53 15-01-31
David Elkins DFI
 Director of Finance/CFO 55 19-11-19
Greg Meyers CTO
 Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Phyllis Yale BRD
 Director/Board Member 66 19-11-19
Peter Arduini BRD
 Director/Board Member 59 16-03-31
Derica Rice BRD
 Director/Board Member 59 20-08-31
More insiders

ETFs positioned on Bristol-Myers Squibb Company

Name Weight AuM 1st Jan change Investor Rating
AGF U.S. MARKET NEUTRAL ANTI-BETA FUND - USD ETF AGF U.S. Market Neutral Anti-Beta Fund - USD
12.97% 215 M€ +12.86% -
BMO MSCI GENOMIC INNOVATION INDEX ETF - CAD ETF BMO MSCI Genomic Innovation Index ETF - CAD
4.99% 2 M€ -.--%
NOMURA NEXT FUNDS INTERNATIONAL EQUITY MSCI-KOKUSAI (YEN-HEDGED) ETF - JPY ETF Nomura NEXT FUNDS International Equity MSCI-KOKUSAI (Yen-Hedged) ETF - JPY
4.01% 18 M€ +2.91% -
More ETFs positioned on Bristol-Myers Squibb Company

Quotes

Date Price Change Volume
24-04-18 48.3 +0.96% 10,917,081
24-04-17 47.84 -0.87% 11,763,053
24-04-16 48.26 -0.52% 11,931,277
24-04-15 48.51 +0.48% 11,943,603
24-04-12 48.28 -1.71% 12,459,210

Delayed Quote Nyse, April 18, 2024 at 04:00 pm EDT

More quotes

Company Profile

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.
Sector
Pharmaceuticals
Calendar
2024-04-25 - Q1 2024 Earnings Release
Related indices
S&P 500
More about the company

Income Statement Evolution

More financial data

Ratings for Bristol-Myers Squibb Company

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
27
Last Close Price
47.84 USD
Average target price
56.33 USD
Spread / Average Target
+17.74%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
BRISTOL-MYERS SQUIBB COMPANY Stock Bristol-Myers Squibb Company
-5.87% 96.96B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+27.97% 676B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+23.58% 554B
JOHNSON & JOHNSON Stock Johnson & Johnson
-7.02% 349B
MERCK & CO., INC. Stock Merck & Co., Inc.
+14.85% 318B
ABBVIE INC. Stock AbbVie Inc.
+6.25% 291B
ASTRAZENECA PLC Stock AstraZeneca PLC
+2.96% 210B
NOVARTIS AG Stock Novartis AG
-0.41% 204B
ROCHE HOLDING AG Stock Roche Holding AG
-10.02% 194B
PFIZER, INC. Stock Pfizer, Inc.
-11.81% 144B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. BMY Stock